efalizumab   Click here for help

GtoPdb Ligand ID: 6593

Synonyms: anti alphaL integrin | antiCD11 alpha | hu1124 | Raptiva®
Approved drug Immunopharmacology Ligand
efalizumab is an approved drug (FDA (2003), EMA (2004))
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Used to treat psoriasis prior to withdrawl from the market.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The molecular target of this monoclonal antibody is ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, aka CD11a). The antibody acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues.